Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233705 | 1.00 | MEN1 (0.55) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL238143 | 0.86 | MEN1 (0.56) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL234144 | 0.86 | KMT2A (0.62) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL234143 | 0.86 | KMT2A (0.62) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL238144 | 0.86 | MEN1 (0.56) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL10026155 | 0.86 | KMT2A (0.62) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL238470 | 0.85 | MEN1 (0.55) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL238469 | 0.85 | MEN1 (0.55) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL236411 | 0.76 | CHRNA7 (0.74) | MEN1CHRNA7KMT2ATDP1PDE4B | |
| SCHEMBL236412 | 0.76 | CHRNA7 (0.74) | MEN1CHRNA7KMT2ATDP1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225940-B1 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION GMBH (AT) | 2014-03-12 | — | — | EP | disclosed |
| US-8293733-B2 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION AG (AT) | 2012-10-23 | — | — | US | disclosed |
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | GAT MICROENCAPSULATION AG (AT) | 2012-01-05 | — | — | US | disclosed |
| EP-2225940-A1 | Oil dispersions of nAChR binding neonicotinoids | GAT Microencapsulation AG (AT) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | CHRND, ITGAM, CHRM2 | MEN1 4692/4885CHRNA7 16/4885KMT2A 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.